secwatch.observer — SEC 8-K summary
======================================

Issuer:     aTYR PHARMA INC (ATYR)
CIK:        0001339970
Form:       8-K
Filed at:   2024-05-29T23:59:59+00:00
Accession:  0000950170-24-065899
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 5.02, 5.07, 5.05, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

aTyr Pharma shareholders approve stock plan increase and report Phase 3 trial enrollment progress
--------------------------------------------------------------------------------

- Shareholders approved amendment to 2015 Stock Plan, increasing shares reserved by 3,000,000 to 10,713,670.
- Svetlana Lucas and Sanjay Shukla elected as Class III directors with majority votes.
- Ratification of Ernst & Young as independent auditor for FY2024 (54.5M for, 327K against).
- Advisory approval of executive compensation (42.5M for, 398K against).
- Phase 3 EFZO-FIT study of efzofitimod in pulmonary sarcoidosis anticipates completing enrollment in Q2 2024; final patient dosing may occur in July 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1339970/000095017024065899/0000950170-24-065899-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1339970/000095017024065899/life-20240522.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-065899

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer